Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Average Recommendation of “Moderate Buy” from Analysts

Travere Therapeutics, Inc. (NASDAQ:TVTX) has been given an average rating of “Moderate Buy” by the fifteen analysts that are covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $17.85.

Several research firms have weighed in on TVTX. Wedbush reiterated an “outperform” rating and set a $13.00 target price on shares of Travere Therapeutics in a report on Wednesday, April 17th. HC Wainwright restated a “buy” rating and set a $17.00 target price on shares of Travere Therapeutics in a report on Wednesday, March 13th. Wells Fargo & Company upped their price target on shares of Travere Therapeutics from $8.00 to $9.00 and gave the company an “equal weight” rating in a report on Friday, February 16th. Guggenheim reissued a “neutral” rating on shares of Travere Therapeutics in a research report on Wednesday, March 27th. Finally, Piper Sandler boosted their price objective on shares of Travere Therapeutics from $10.00 to $11.00 and gave the company a “neutral” rating in a research report on Thursday, January 18th.

Travere Therapeutics Stock Performance

Shares of TVTX stock opened at $5.74 on Wednesday. The stock has a market cap of $436.87 million, a PE ratio of -3.57 and a beta of 0.58. The stock has a 50-day moving average of $7.46 and a 200-day moving average of $7.69. The company has a debt-to-equity ratio of 1.88, a current ratio of 3.47 and a quick ratio of 3.41. Travere Therapeutics has a one year low of $5.25 and a one year high of $22.75.

Travere Therapeutics (NASDAQ:TVTX) last issued its earnings results on Thursday, February 15th. The company reported ($1.16) EPS for the quarter, beating the consensus estimate of ($1.27) by $0.11. The firm had revenue of $45.06 million during the quarter, compared to the consensus estimate of $41.25 million. Travere Therapeutics had a negative net margin of 56.02% and a negative return on equity of 177.97%. As a group, sell-side analysts expect that Travere Therapeutics will post -3.1 earnings per share for the current year.

Insider Buying and Selling at Travere Therapeutics

In other news, CFO Christopher R. Cline sold 3,818 shares of the business’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $8.53, for a total transaction of $32,567.54. Following the transaction, the chief financial officer now directly owns 70,903 shares in the company, valued at approximately $604,802.59. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Travere Therapeutics news, SVP William E. Rote sold 4,764 shares of the firm’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $8.71, for a total transaction of $41,494.44. Following the completion of the sale, the senior vice president now owns 80,720 shares of the company’s stock, valued at approximately $703,071.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Christopher R. Cline sold 3,818 shares of the company’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $8.53, for a total transaction of $32,567.54. Following the completion of the transaction, the chief financial officer now owns 70,903 shares in the company, valued at $604,802.59. The disclosure for this sale can be found here. Insiders sold a total of 34,773 shares of company stock worth $300,625 over the last quarter. 4.06% of the stock is currently owned by insiders.

Institutional Trading of Travere Therapeutics

A number of hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC bought a new position in Travere Therapeutics during the 3rd quarter worth $1,179,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Travere Therapeutics by 32.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,511 shares of the company’s stock worth $148,000 after purchasing an additional 4,007 shares in the last quarter. Emerald Advisers LLC increased its holdings in shares of Travere Therapeutics by 64.9% during the third quarter. Emerald Advisers LLC now owns 1,060,302 shares of the company’s stock worth $9,479,000 after purchasing an additional 417,250 shares during the period. Emerald Mutual Fund Advisers Trust boosted its stake in shares of Travere Therapeutics by 44.4% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 764,603 shares of the company’s stock valued at $6,836,000 after buying an additional 235,085 shares during the period. Finally, Cheyne Capital Management UK LLP bought a new position in Travere Therapeutics during the 3rd quarter worth $234,000.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.